Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381046 | 0.83 | KDM4E (0.69) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL1934753 | 0.81 | RAB9A (0.57) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL30593991 | 0.81 | RAB9A (0.57) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL25097159 | 0.79 | KMT2A (0.54) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL4501507 | 0.79 | KMT2A (0.46) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL4237518 | 0.79 | RAB9A (0.56) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL5139472 | 0.79 | KMT2A (0.54) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL4692505 | 0.79 | KMT2A (0.54) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL11997717 | 0.79 | KMT2A (0.50) | KMT2ARAB9AKDM4ENPC1MAPT | |
| SCHEMBL31536297 | 0.79 | KMT2A (0.50) | KMT2ARAB9AKDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | KMT2A 2078/4885RAB9A 2722/4885KDM4E 713/4885 |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | KMT2A 2923/4885RAB9A 1828/4885KDM4E 1951/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | KMT2A 3716/4885RAB9A 3255/4885KDM4E 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.